Neoadjuvant chemotherapy (NACT) has been regarded a standard treatment for advanced ovarian cancers for decades. Among patients who are poor candidates for primary debulking surgery (PDS), NACT is likely their only option in clinical practice. However, NACT failed to show any survival benefit in the reported randomized controlled trials (RCTs) and the meta-analyses, compared with PDS. This phenomenon raises concerns over the unfavorable influence of NACT, that is, the potential risk of inducing platinum resistance. In this review, we reveal the risk of NACT-related platinum resistance by summarizing the experimental and clinical evidence and discuss new attempts to avoid this phenomenon.
基金：
National Science and Technology Major Sub-Project [2018ZX10301402-002]; Technical Innovation Special Project of Hubei Province [2018ACA138]; National Natural Science Foundation of China [81772787]; Fundamental Research Funds for the Central Universities [2019kfyXMBZ024]
：
医学